{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:36:10Z","timestamp":1794645370127,"version":"4.9.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":786,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1097\/apo.0000000000000445","type":"journal-article","created":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T16:02:58Z","timestamp":1638115378000},"page":"507-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society"],"prefix":"10.1016","volume":"10","author":[{"given":"Voraporn","family":"Chaikitmongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Fariza","family":"Ngah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Ohji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/APO.0000000000000445_bib1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1097\/APO.0000000000000445_bib2","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1097\/APO.0000000000000445_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib4","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","article-title":"Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration","volume":"34","author":"Ross","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1097\/APO.0000000000000445_bib5","first-page":"296","article-title":"Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel","volume":"6","author":"Koh","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1097\/APO.0000000000000445_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1097\/APO.0000000000000445_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.APO.0000656992.00746.48","article-title":"Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment","volume":"9","author":"Chaikitmongkol","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1097\/APO.0000000000000445_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1097\/APO.0000000000000445_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.oret.2019.10.019","article-title":"Real-world treatment outcomes of age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Fenner","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1097\/APO.0000000000000445_bib12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.APO.0000656976.47696.7d","article-title":"Genetic association of age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"9","author":"Chen","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1097\/APO.0000000000000445_bib15","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/APO.0000000000000445_bib17","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/APO.0000000000000445_bib18","doi-asserted-by":"crossref","unstructured":"Mitchell P, Holz FG, Hykin P, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study. Retina 2021; Online ahead of print. doi:10.1097\/IAE.0000000000003128.","DOI":"10.1097\/IAE.0000000000003128"},{"key":"10.1097\/APO.0000000000000445_bib19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/bjophthalmol-2014-305076","article-title":"Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study","volume":"99","author":"Ogura","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"10.1097\/APO.0000000000000445_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2147\/OPTH.S303884","article-title":"Real-world effectiveness, treatment pattern, and safety of ranibizumab in Korean patients with neovascular age-related macular degeneration: subgroup analyses from the LUMINOUS study","volume":"15","author":"Sagong","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib22","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib24","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/aos.13031","article-title":"Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12\u200amonth study","volume":"95","author":"Hatz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib25","doi-asserted-by":"crossref","unstructured":"Daien V, Finger RP, Talks JS, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol 2020; Online ahead of print. doi:10.1136\/bjophthalmol-2020-317434.","DOI":"10.1136\/bjophthalmol-2020-317434"},{"key":"10.1097\/APO.0000000000000445_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","article-title":"Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial","volume":"138","author":"Kertes","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib28","unstructured":"Stone TW, ed., American Society of Retina Specialists (ASRS) 2019 Preferences and Trends membership survey. Chicago, IL, US: 2019."},{"key":"10.1097\/APO.0000000000000445_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian Treat-and-Extend Analysis Trial with Ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib31","first-page":"117","article-title":"Efficacy of intravitreal aflibercept administered using treat-and-extend regimen over 2\u200ayears in patients with neovascular age-related macular degeneration: 1-year ARIES results","volume":"60","author":"Mitchell","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1097\/APO.0000000000000445_bib32","first-page":"8","article-title":"Twelve-month outcomes of aflibercept versus ranibizumab for neovascular age-related macular degeneration (AMD)","volume":"32","author":"Almuhtaseb","year":"2018","journal-title":"Eye"},{"key":"10.1097\/APO.0000000000000445_bib33","doi-asserted-by":"crossref","first-page":"e820","DOI":"10.1111\/aos.14399","article-title":"Bimonthly, treat-and-extend and as-needed ranibizumab in na\u00efve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study","volume":"98","author":"L\u00f3pez G\u00e1lvez","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib34","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1097\/APO.0000000000000445_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","article-title":"The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis","volume":"192","author":"Okada","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib36","unstructured":"Hamoud A, Hodosi K, Zacharaki F, et al. One year real-world outcomes of anti-VEGF therapy in neovascular age related macular degeneration. Presented at the 20th European Society of Retina Specialists (EURETINA) Congress; October 2\u20134, 2020."},{"key":"10.1097\/APO.0000000000000445_bib37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12886-018-1005-x","article-title":"Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia","volume":"18","author":"Jaki Mekjavi\u0107","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib38","unstructured":"Spooner K, Fraser-Bell S, Cozzi M, et al. Comparison of macular atrophy in eyes with neovascular age-related macular degeneration treated with VEGF inhibitors using a treat-and-extend or pro re nata regimen: 4-year results of the MANEX study. Clin Exp Ophthalmol 2019; 63."},{"key":"10.1097\/APO.0000000000000445_bib39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","article-title":"Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors using a treat-and-extend or a pro re nata regimen: four-year results of the MANEX study","volume":"127","author":"Spooner","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12325-017-0483-1","article-title":"A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom","volume":"34","author":"Johnston","year":"2017","journal-title":"Adv Ther"},{"key":"10.1097\/APO.0000000000000445_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1089\/jop.2017.0006","article-title":"Comparison of strategies of treatment with ranibizumab in newly-diagnosed cases of neovascular age-related macular degeneration","volume":"33","author":"Garweg","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1097\/APO.0000000000000445_bib42","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/aos.13989","article-title":"Better visual outcome at 1\u200ayear with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration","volume":"97","author":"Aurell","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib46","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00417-019-04360-9","article-title":"Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration","volume":"257","author":"Abdin","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/jop.2017.0031","article-title":"Real-life experience with aflibercept and ranibizumab in the treatment of newly diagnosed neovascular age-related macular degeneration over 24\u200amonths","volume":"33","author":"Garweg","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1097\/APO.0000000000000445_bib48","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1007\/s12325-020-01298-x","article-title":"Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2\u200ayears: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"10.1097\/APO.0000000000000445_bib49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib51","first-page":"100","article-title":"Treat-and-extend anti-VEGF therapy for exudative age-related macular degeneration: long-term results","volume":"60","author":"Delaunay","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1097\/APO.0000000000000445_bib52","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/JCMA.0000000000000138","article-title":"Priority options of anti-vascular endothelial growth factor agents in wet age-related macular degeneration under the National Health Insurance Program","volume":"82","author":"Chou","year":"2019","journal-title":"J Chin Med Assoc"},{"key":"10.1097\/APO.0000000000000445_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00417-019-04569-8","article-title":"Off-label use of bevacizumab for wet age-related macular degeneration in Europe","volume":"258","author":"Bro","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12886-019-1086-1","article-title":"A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand","volume":"19","author":"Kumluang","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib55","first-page":"379","article-title":"Impact of polyp regression on 2-year outcomes of intravitreal aflibercept injections: a treat-and-extend regimen for polypoidal choroidal vasculopathy","volume":"72","author":"Morizane-Hosokawa","year":"2018","journal-title":"Acta Med Okayama"},{"key":"10.1097\/APO.0000000000000445_bib56","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40123-020-00312-3","article-title":"One-year results of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"9","author":"Tamachi","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1097\/APO.0000000000000445_bib57","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","article-title":"Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy","volume":"255","author":"Morimoto","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib58","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0492-7","article-title":"One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"61","author":"Hosokawa","year":"2017","journal-title":"Jpn J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib59","doi-asserted-by":"crossref","unstructured":"Teo KYC, Jordan-Yu JM, Tan ACS, et al. Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy. Br J Ophthalmol 2021; Online ahead of print. doi:10.1136\/bjophthalmol-2020-318354.","DOI":"10.1136\/bjophthalmol-2020-318354"},{"key":"10.1097\/APO.0000000000000445_bib60","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","article-title":"Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study","volume":"4","author":"Maruko","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1097\/APO.0000000000000445_bib61","unstructured":"Ohji M, Okada AA, Takahashi K, et al. Intravitreal aflibercept treat-and-extend dosing for wet age-related macular degeneration: ALTAIR 96-week results. Presented at the 12th Congress of the Asia-Pacific Vitreo-retina Society (APVRS); Seoul, South Korea, December 14\u201316, 2018."},{"key":"10.1097\/APO.0000000000000445_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/ijo.IJO_902_17","article-title":"Optical coherence tomography: a guide to interpretation of common macular diseases","volume":"66","author":"Bhende","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1097\/APO.0000000000000445_bib64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"10.1097\/APO.0000000000000445_bib65","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/bjophthalmol-2015-308264","article-title":"Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times","volume":"100","author":"Fauser","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib66","first-page":"3025","article-title":"Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration","volume":"53","author":"Gaudreault","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1097\/APO.0000000000000445_bib67","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib68","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib69","unstructured":"Food and Drug Administration (FDA)FDA drug approval package: BEOVU (brolucizumab-dbll); Non-clinical review(s) 2019."},{"key":"10.1097\/APO.0000000000000445_bib70","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib71","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IAE.0000000000002713","article-title":"Suspending treatment of neovascular age-related macular degeneration in cases of futility","volume":"40","author":"Wong","year":"2020","journal-title":"Retina"},{"key":"10.1097\/APO.0000000000000445_bib72","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0000000000002384","article-title":"Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy","volume":"40","author":"Cho","year":"2020","journal-title":"Retina"},{"key":"10.1097\/APO.0000000000000445_bib73","doi-asserted-by":"crossref","first-page":"e0235213","DOI":"10.1371\/journal.pone.0235213","article-title":"Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy","volume":"15","author":"Ito","year":"2020","journal-title":"PLoS One"},{"key":"10.1097\/APO.0000000000000445_bib74","doi-asserted-by":"crossref","unstructured":"Chaikitmongkol V, Upaphong P, Patikulsila D, et al. Timing of complete polypoidal regression following intravitreous aflibercept treatments in polypoidal choroidal vasculopathy. Ophthalmol Retina 2021; Online ahead of print. doi:10.1016\/j.oret.2021.03.012.","DOI":"10.1016\/j.oret.2021.03.012"},{"key":"10.1097\/APO.0000000000000445_bib75","unstructured":"United Nations\u2013Department of Economic and Social Affairs. World Population Ageing 2019: Highlights; 2019."},{"key":"10.1097\/APO.0000000000000445_bib76","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40123-018-0139-5","article-title":"Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: evidence from a clinical setting","volume":"7","author":"Eleftheriadou","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"10.1097\/APO.0000000000000445_bib77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","article-title":"Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen","volume":"3","author":"Traine","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1097\/APO.0000000000000445_bib78","doi-asserted-by":"crossref","unstructured":"Lukic M, Eleftheriadou M, Hamilton RD, et al. Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: results from real-life setting. Eur J Ophthalmol 2020; Online ahead of print. doi:10.1177\/1120672120938565.","DOI":"10.1177\/1120672120938565"},{"key":"10.1097\/APO.0000000000000445_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib80","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib81","first-page":"35","article-title":"What to do when anti-VEGF therapy \u201cfails\u201d","volume":"7","author":"Slakter","year":"2010","journal-title":"Retin Physician"},{"key":"10.1097\/APO.0000000000000445_bib82","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00417-021-05097-0","article-title":"Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure","volume":"259","author":"Korobelnik","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib83","doi-asserted-by":"crossref","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol 2021; Online ahead of print. doi:10.1007\/s00417-021-05174-4.","DOI":"10.1007\/s00417-021-05174-4"},{"key":"10.1097\/APO.0000000000000445_bib84","doi-asserted-by":"crossref","unstructured":"Wasser LM, Weill Y, Brosh K, et al. The impact of COVID-19 on intravitreal injection compliance. SN Compr Clin Med 2020; 1\u20134.","DOI":"10.1007\/s42399-020-00614-4"},{"key":"10.1097\/APO.0000000000000445_bib85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/APO.0000000000000305","article-title":"Impact of COVID-19 on ophthalmology and future practice of medicine","volume":"9","author":"Wan","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1097\/APO.0000000000000445_bib86","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists (RANZCO). RANZCO triage guidelines for fellows and other health professionals. Available at https:\/\/ranzco.edu\/policies_and_guideli\/ranzco-covid-19-triage-guidelines\/. Accessed June 2021."},{"key":"10.1097\/APO.0000000000000445_bib87","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/jcm9051522","article-title":"Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies","volume":"9","author":"Plyukhova","year":"2020","journal-title":"J Clin Med"},{"key":"10.1097\/APO.0000000000000445_bib88","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2016.02.046","article-title":"Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials","volume":"123","author":"Kitchens","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1097\/APO.0000000000000445_bib89","unstructured":"Novartis. Beovu (brolucizumab); Global use and safety information for healthcare professionals. Available at https:\/\/www.brolucizumab.info\/overview. Accessed June 2021."},{"key":"10.1097\/APO.0000000000000445_bib90","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/APO.0000000000000308","article-title":"COVID-19: Ocular manifestations and the APAO prevention guidelines for ophthalmic practices","volume":"9","author":"Wong","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1097\/APO.0000000000000445_bib91","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/OPTH.S174560","article-title":"Initiation and maintenance of a treat-and-extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group","volume":"12","author":"Amoaku","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib92","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2147\/OPTH.S145732","article-title":"Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update","volume":"11","author":"Patel","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1097\/APO.0000000000000445_bib93","first-page":"2390","article-title":"Three year real world outcomes of aflibercept treatment for wet age-related macular degeneration and results of variable treatment regimes in the second year","volume":"59","author":"Mahmood","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1097\/APO.0000000000000445_bib94","first-page":"891","article-title":"Ranibizumab efficacy in nAMD using a treat and extend regimen: a comparison between the interventional TREND and non-interventional LUMINOUS studies","volume":"58","author":"Mitchell","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1097\/APO.0000000000000445_bib95","first-page":"CD012208","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1097\/APO.0000000000000445_bib96","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/2040622320953349","article-title":"Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis","volume":"11","author":"Ye","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1097\/APO.0000000000000445_bib97","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pharmaceutics10010021","article-title":"Extended duration vascular endothelial growth factor inhibition in the eye: failures, successes, and future possibilities","volume":"10","author":"Stewart","year":"2018","journal-title":"Pharmaceutics"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216209892300049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216209892300049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1097\/APO.0000000000000445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:17:28Z","timestamp":1761873448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216209892300049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S216209892300049X"],"URL":"https:\/\/doi.org\/10.1097\/apo.0000000000000445","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/APO.0000000000000445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology. Published by Elsevier Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}